Literature DB >> 17710515

Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat.

Marian Geldof1, Jan Freijer, Ludy van Beijsterveldt, Meindert Danhof.   

Abstract

INTRODUCTION: A pharmacokinetic (PK) model is proposed for estimation of total and free brain concentrations of fluvoxamine.
MATERIALS AND METHODS: Rats with arterial and venous cannulas and a microdialysis probe in the frontal cortex received intravenous infusions of 1, 3.7 or 7.3 mg.kg(-1) of fluvoxamine. ANALYSIS: With increasing dose a disproportional increase in brain concentrations was observed. The kinetics of brain distribution was estimated by simultaneous analysis of plasma, free brain ECF and total brain tissue concentrations. The PK model consists of three compartments for fluvoxamine concentrations in plasma in combination with a catenary two compartment model for distribution into the brain. In this catenary model, the mass exchange between a shallow perfusion-limited and a deep brain compartment is described by a passive diffusion term and a saturable active efflux term.
RESULTS: The model resulted in precise estimates of the parameters describing passive influx into (k in) of 0.16 min(-1) and efflux from the shallow brain compartment (k out) of 0.019 min(-1) and the fluvoxamine concentration at which 50% of the maximum active efflux (C 50) is reached of 710 ng.ml(-1). The proposed brain distribution model constitutes a basis for precise characterization of the PK-PD correlation of fluvoxamine by taking into account the non-linearity in brain distribution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710515      PMCID: PMC2279155          DOI: 10.1007/s11095-007-9390-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics.

Authors:  M Hammarlund-Udenaes
Journal:  Adv Drug Deliv Rev       Date:  2000-12-15       Impact factor: 15.470

Review 3.  Antidepressants: update on new agents and indications.

Authors:  Adrienne Z Ables; Otis L Baughman
Journal:  Am Fam Physician       Date:  2003-02-01       Impact factor: 3.292

Review 4.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level.

Authors:  S Benmansour; M Cecchi; D A Morilak; G A Gerhardt; M A Javors; G G Gould; A Frazer
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

6.  Modeling population pharmacokinetics of lidocaine: should cardiac output be included as a patient factor?

Authors:  J A Kuipers; F Boer; A de Roode; E Olofsen; J G Bovill; A G Burm
Journal:  Anesthesiology       Date:  2001-04       Impact factor: 7.892

7.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

8.  Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans.

Authors:  Donald E Mager; William J Jusko
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

9.  Inhibition of P-glycoprotein by newer antidepressants.

Authors:  Johanna Weiss; Sven-Maria Gregor Dormann; Meret Martin-Facklam; Christian Johannes Kerpen; Nahal Ketabi-Kiyanvash; Walter Emil Haefeli
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

10.  Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior.

Authors:  Marian Geldof; Jan Freijer; Ludy van Beijsterveldt; Patrick C M Vermote; Anton A Megens; Meindert Danhof
Journal:  Eur J Pharm Sci       Date:  2007-07-28       Impact factor: 4.384

View more
  8 in total

Review 1.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

2.  Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.

Authors:  Saeed Alqahtani; Amal Kaddoumi
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 3.  In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition.

Authors:  Yukiko Murata; Sibylle Neuhoff; Amin Rostami-Hodjegan; Hiroyuki Takita; Zubida M Al-Majdoub; Kayode Ogungbenro
Journal:  AAPS J       Date:  2022-01-13       Impact factor: 4.009

4.  Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex.

Authors:  M Geldof; J I Freijer; L van Beijsterveldt; X Langlois; M Danhof
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

5.  Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.

Authors:  R Clinckers; I Smolders; Y Michotte; G Ebinger; M Danhof; R A Voskuyl; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-10-06       Impact factor: 8.739

Review 6.  Modeling bioavailability to organs protected by biological barriers.

Authors:  Nadia Quignot
Journal:  In Silico Pharmacol       Date:  2013-05-31

7.  Pharmacokinetic Modeling of the Impact of P-glycoprotein on Ondansetron Disposition in the Central Nervous System.

Authors:  Manting Chiang; Hyun-Moon Back; Jong Bong Lee; Sarah Oh; Tiffany Guo; Simone Girgis; Celine Park; Simon Haroutounian; Leonid Kagan
Journal:  Pharm Res       Date:  2020-09-28       Impact factor: 4.200

8.  Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model.

Authors:  Roberto Lozano; Nieves Domeque; Alberto-Fermin Apesteguia
Journal:  Clin Pharmacol       Date:  2013-09-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.